CD47 and lymphoma: In contrast, limited TGI (<50%) was observed across solid tumor models treated with 10 mg/kg of ZL-1201 (Supplementary Fig. S7), suggesting that CD47 blockade may promote antitumor activities more efficiently in lymphoma than in solid tumors.